In the Year of the Weight-Loss Pill, Lilly Still Leads GLP-1s

Core Insights - The introduction of pill versions of GLP-1 drugs is expected in 2026, but analysts believe that Eli Lilly will maintain its competitive edge in obesity and diabetes treatment for several years to come [1] Company Analysis - Eli Lilly is currently leading the market in obesity and diabetes treatments, with a strong position that is anticipated to remain stable despite the upcoming competition from oral GLP-1 drugs [1] Industry Outlook - The arrival of oral GLP-1 medications in 2026 may change the landscape of obesity and diabetes treatment, but Eli Lilly's established market presence and ongoing innovations are expected to sustain its leadership [1]